This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
GoHealth (GOCO.Q) Aandelenoverzicht
GoHealth, Inc. is een marktplaats voor ziektekostenverzekeringen en een op Medicare gericht digitaal gezondheidsbedrijf in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 2 meer risico's
GOCO.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
GoHealth, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.34 |
| 52 Week Hoogtepunt | US$6.61 |
| 52 Week Laag | US$0.27 |
| Bèta | 1.23 |
| 1 maand verandering | -3.71% |
| 3 maanden verandering | -73.04% |
| 1 Jaar Verandering | -94.39% |
| 3 jaar verandering | -98.11% |
| 5 jaar verandering | -99.75% |
| Verandering sinds IPO | -99.88% |
Recent nieuws en updates
Narratiefupdate • Jul 17
GOCO.Q: Chapter 11 Restructuring Will Drive Future Upside After Nasdaq Delisting
Analysts have reduced their fair value estimate for GoHealth from $5.13 to $2.75 per share, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for GoHealth GoHealth and several affiliates filed voluntary petitions for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 7, 2026, with reported assets in the range of US$500 million to US$1b and liabilities in the range of US$1b to US$10b (Bankruptcy Filing).Narratiefupdate • Jun 15
GOCO: Chapter 11 Reorganization Will Drive Future Upside Despite Imminent Delisting
Analysts have trimmed their price targets on GoHealth, citing slightly softer revenue growth assumptions and revised P/E outlooks following a recent downgrade highlighted in Street research. What's in the News GoHealth and certain subsidiaries filed voluntary Chapter 11 petitions in the US Bankruptcy Court for the District of Delaware on June 7, 2026, seeking reorganization with listed assets of $500 million to $1 billion and liabilities of $1 billion to $10 billion, according to court filings.Recent updates
Narratiefupdate • Jul 17
GOCO.Q: Chapter 11 Restructuring Will Drive Future Upside After Nasdaq Delisting
Analysts have reduced their fair value estimate for GoHealth from $5.13 to $2.75 per share, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for GoHealth GoHealth and several affiliates filed voluntary petitions for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 7, 2026, with reported assets in the range of US$500 million to US$1b and liabilities in the range of US$1b to US$10b (Bankruptcy Filing).Narratiefupdate • Jun 15
GOCO: Chapter 11 Reorganization Will Drive Future Upside Despite Imminent Delisting
Analysts have trimmed their price targets on GoHealth, citing slightly softer revenue growth assumptions and revised P/E outlooks following a recent downgrade highlighted in Street research. What's in the News GoHealth and certain subsidiaries filed voluntary Chapter 11 petitions in the US Bankruptcy Court for the District of Delaware on June 7, 2026, seeking reorganization with listed assets of $500 million to $1 billion and liabilities of $1 billion to $10 billion, according to court filings.Narratiefupdate • Jun 01
GOCO: Higher Growth Assumptions Will Support Upside Despite Nasdaq Listing Risk
Analysts have adjusted their price target on GoHealth from $4.70 to $5.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following recent research, including a downgrade at Freedom Broker. What's in the News GoHealth reported that it will be unable to file its next 10-Q with the SEC by the required deadline, citing a delayed SEC filing as of May 18, 2026.
Narratiefupdate • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.Narratiefupdate • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.Narratiefupdate • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).Narratiefupdate • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.Narratiefupdate • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.Narratiefupdate • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.Narratiefupdate • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.Narratiefupdate • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.Narratiefupdate • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.Narratiefupdate • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.Narratiefupdate • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.Narratiefupdate • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.Narratiefupdate • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.Narratiefupdate • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
Nieuw narratief • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Rendement voor aandeelhouders
| GOCO.Q | US Insurance | US Markt | |
|---|---|---|---|
| 7D | -7.8% | -0.6% | -0.2% |
| 1Y | -94.4% | 2.8% | 11.9% |
Rendement versus industrie: GOCO.Q presteerde slechter dan de US Insurance -sector, die het afgelopen jaar een rendement van 2.8 % opleverde.
Rendement versus markt: GOCO.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 11.9 % opleverde.
Prijsvolatiliteit
| GOCO.Q volatility | |
|---|---|
| GOCO.Q Average Weekly Movement | 19.0% |
| Insurance Industry Average Movement | 4.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van GOCO.Q is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van GOCO.Q is het afgelopen jaar gestegen van 14% naar 19%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2001 | 850 | Vijay Kotte | www.gohealth.com |
GoHealth, Inc. is een marktplaats voor ziektekostenverzekeringen en een op Medicare gericht digitaal gezondheidsbedrijf in de Verenigde Staten. Het bedrijf biedt Medicare-plannen aan, waaronder Medicare-voordeel, Medicare-supplementen, plannen voor geneesmiddelen op recept en plannen voor speciale behoeften. Het bedrijf heeft ook een technologieplatform dat gebruik maakt van machine-learning algoritmen van het koopgedrag van verzekeraars om het proces van het afstemmen van een gezondheidsplan op de specifieke behoeften van een consument opnieuw vorm te geven.
GoHealth, Inc. Samenvatting
| GOCO.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$9.08m |
| Inkomsten(TTM) | -US$293.88m |
| Inkomsten(TTM) | US$152.79m |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs GOCO.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| GOCO.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$152.79m |
| Kosten van inkomsten | US$65.17m |
| Brutowinst | US$87.62m |
| Overige uitgaven | US$381.50m |
| Inkomsten | -US$293.88m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -17.61 |
| Brutomarge | 57.34% |
| Nettowinstmarge | -192.35% |
| Schuld/Eigen Vermogen Verhouding | -949.5% |
Hoe presteerde GOCO.Q op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/21 11:02 |
| Aandelenkoers aan het einde van de dag | 2026/07/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
GoHealth, Inc. wordt gevolgd door 13 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |
| Elizabeth Anderson | Evercore ISI |